, /PRNewswire/ -- MedGenome, a leading provider of multiomics solutions, today announced the acquisition of a PacBio Revio sequencing system. This latest addition to MedGenome's technology portfolio will significantly bolster their long-read sequencing capabilities, enabling researchers to delve deeper into the complexities of the genome and advance scientific discoveries. PacBio's platforms are known for their ability to deliver highly accurate long-read sequencing data, providing crucial insights into complex genomic regions previously inaccessible with short-read technologies.
This acquisition allows MedGenome to offer end-to-end solutions for applications including: This announcement comes on the heels of MedGenome's recent to sequence the genome of the Dune Scorpion in collaboration with PacBio and the California Academy of Sciences. The project highlights the growing demand for highly accurate long-read sequencing in biodiversity studies, and the Revio system will play a key role in enabling such research. "We are excited to add the PacBio Revio system to our suite of cutting-edge genomic technologies," said Dr.
, Chairman of the Board at MedGenome. "This investment underscores our commitment to providing researchers with the most advanced end-to-end solutions to drive groundbreaking discoveries in healthcare, personalized medicine, and beyond." "We're thrilled to partner with MedGenome as the first commercial service provider in the of to offer Revio's advanced long-re.